CRSP CRISPR Therapeutics AG

Price (delayed)

$188.49

Market cap

$13.32B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.22

Enterprise value

$12.31B

Sector: Healthcare
Industry: Biotechnology

Highlights

The equity has soared by 127% YoY and by 48% QoQ
CRSP's quick ratio has soared by 107% YoY and by 29% QoQ
The debt has increased by 18% year-on-year but it has declined by 2% since the previous quarter
The company's gross profit has shrunk by 73% QoQ and by 64% YoY
The revenue has dropped by 73% since the previous quarter and by 64% year-on-year

Key stats

What are the main financial stats of CRSP
Market
Shares outstanding
70.65M
Market cap
$13.32B
Enterprise value
$12.31B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
9.85
Price to sales (P/S)
170.9
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
159.09
Earnings
Revenue
$77.37M
EBIT
-$210.32M
EBITDA
-$202.27M
Free cash flow
-$166.85M
Per share
EPS
-$3.22
Free cash flow per share
-$2.38
Book value per share
$19.14
Revenue per share
$1.1
TBVPS
$21.17
Balance sheet
Total assets
$1.49B
Total liabilities
$141.72M
Debt
$49.21M
Equity
$1.34B
Working capital
$1.31B
Liquidity
Debt to equity
0.04
Current ratio
16.53
Quick ratio
16.43
Net debt/EBITDA
4.99
Margins
EBITDA margin
-261.5%
Gross margin
100%
Net margin
-273.1%
Operating margin
-304.6%
Efficiency
Return on assets
-18.4%
Return on equity
-20.7%
Return on invested capital
-123%
Return on capital employed
-15%
Return on sales
-271.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CRSP stock price

How has the CRISPR Therapeutics AG stock price performed over time
Intraday
1.83%
1 week
-5.7%
1 month
10.82%
1 year
222.81%
YTD
23.11%
QTD
23.11%

Financial performance

How have CRISPR Therapeutics AG's revenue and profit performed over time
Revenue
$77.37M
Gross profit
$77.37M
Operating income
-$235.69M
Net income
-$211.28M
Gross margin
100%
Net margin
-273.1%
The company's gross profit has shrunk by 73% QoQ and by 64% YoY
The revenue has dropped by 73% since the previous quarter and by 64% year-on-year

Growth

What is CRISPR Therapeutics AG's growth rate over time

Valuation

What is CRISPR Therapeutics AG stock price valuation
P/E
N/A
P/B
9.85
P/S
170.9
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
159.09
The price to book (P/B) is 153% higher than the last 4 quarters average of 3.9 and 101% higher than the 5-year quarterly average of 4.9
The equity has soared by 127% YoY and by 48% QoQ
The revenue has dropped by 73% since the previous quarter and by 64% year-on-year
The price to sales (P/S) is 29% lower than the 5-year quarterly average of 240.3

Efficiency

How efficient is CRISPR Therapeutics AG business performance

Dividends

What is CRSP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRSP.

Financial health

How did CRISPR Therapeutics AG financials performed over time
CRSP's quick ratio has soared by 107% YoY and by 29% QoQ
CRISPR Therapeutics AG's total assets has soared by 106% YoY and by 42% from the previous quarter
The debt is 96% smaller than the equity
The equity has soared by 127% YoY and by 48% QoQ
CRSP's debt to equity is down by 43% YoY and by 33% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.